TFF Pharmaceuticals, which is developing dry powder inhaled and nasal formulations based on its thin film freezing particle engineering technology, has announced the appointment of Zamaneh Mikhak as Chief Medical Officer. Mikhak was most recently Senior VP and Head of Clinical Development at Cogent Biosciences, and her prior industry experience includes roles at Boston Pharmaceuticals, Kiniksa Pharmaceuticals, and Sanofi Genzyme.
TFF’s pipeline includes includes inhaled dry powder formulations of voriconazole for invasive pulmonary aspergillosis; tacrolimus for the prevention of organ transplant rejection; niclosamide for COVID-19; Aug-3387 mAb for COVID-19; and an inhaled mAb against Ebola; as well as dry powder vaccines, including intranasal dry powder vaccines.
TFF Interim CEO Harlan Weisman commented, “We are pleased to welcome Dr. Mikhak to TFF Pharmaceuticals as our Chief Medical Officer. Dr. Mikhak brings to TFF an extraordinary depth of industry and clinical experience that will be instrumental in helping us advance our clinical-stage pipeline candidates and expand our pipeline. This appointment also signals the natural evolution of our company, as we seek to further expand the clinical applications of thin film freezing to help realize the full potential of our technology platform.”
Mikhak said, “I am delighted to be joining TFF Pharmaceuticals, particularly at such an important and exciting period in the company’s growth. The therapeutic applications of thin film freezing hold significant potential for optimizing drug delivery to improve clinical outcomes, as already demonstrated through the recently reported compassionate use data from the inhaled voriconazole powder program. I look forward to working with my new TFF colleagues as we embark on this journey together.”
Read the TFF Pharmaceuticals press release.
